HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verel, I. Articles by van Dongen, G. A.M.S Search for Related Content PubMed PubMed Citation Articles by Verel, I. Articles by van Dongen, G. A.M.S

Quantitative ⁸⁹Zr Immuno-PET for In Vivo Scouting of ⁹⁰Y-Labeled Monoclonal Antibodies in Xenograft-Bearing Nude Mice

¹ Department of Otolaryngology/Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
² Radionuclide Center, VU University, Amsterdam, The Netherlands
³ PET Center, VU University Medical Center, Amsterdam, The Netherlands
⁴ Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands

View larger version (18K): [in a new window]   FIGURE 1. Simplified 89Zr decay scheme (modified from ICRP publication (9)). Only transitions in excess of 0.1% abundance are shown. EC = electron capture; IT = isomeric transition; t1/2 = half-life.

View larger version (18K): [in a new window]   FIGURE 2. Biodistribution of coinjected cmAb U36-N-sucDf-89Zr (0.37 MBq, white bars) and cmAb U36-p-BSCN-Bz-DOTA-88Y (0.13 MBq, black bars) in HNX-OE xenograft-bearing mice at 3 h (A), 24 h (B), 48 h (C), 72 h (D), and 144 h (E) after injection. At the indicated time points, 4 mice were bled, sacrificed, and dissected, and radioactivity levels (%ID/g ± SE) of blood, tumor, organs, and gastrointestinal contents were assessed. BL = blood; TU = tumor; SM = sternum; HE = heart; LU = lung; LI = liver; SP = spleen; KI = kidney; MU = muscle; TB = thighbone; CO = colon; CC = colon content; IL = ileum; IC = ileum content; ST = stomach; SC = stomach content.

View larger version (13K): [in a new window]   FIGURE 3. 89Zr-counting-rate linearity determination with HRRT PET camera. Plot is of PET-assessed radioactivity in cylinder phantom versus radioactivity based on dose calibrator measurements. Note presence of linearity, except for highest radioactivity measurement.

View larger version (13K): [in a new window]   FIGURE 4. Spatial resolution determination for 89Zr (dotted line) with HRRT PET camera. Line profile was drawn through image of line source containing 89Zr. For comparison, line profile for 18F (solid line) is also shown.

View larger version (13K): [in a new window]   FIGURE 5. HSRCs (A) and sphere size estimations (B) for 89Zr () with HRRT PET camera. For comparison, 18F () data are also shown. For this purpose, 50% isocontour ROIs were drawn around spheres of Jaszczak phantom.

View larger version (57K): [in a new window]   FIGURE 6. HRRT PET images of HNX-OE xenograft-bearing mouse injected with cmAb U36-N-sucDf-89Zr (3.7 MBq) at 72 h after injection. Coronal image plane (A) in which both tumors (left, 124 mg; right, 26 mg) were visible was chosen. Transaxial image planes in which right tumor was optimally visible (B, top) or left tumor was optimally visible (B, middle and bottom) were chosen. Bottom panel of B illustrates approach to arrive at ring-shaped area used for surroundings determination.

View larger version (15K): [in a new window]   FIGURE 7. Correlation between PET-assessed tumor uptake and ex vivo-assessed tumor uptake. HNX-OE xenograft-bearing mice were injected with cmAb U36-N-sucDf-89Zr (3.7 MBq) and scanned at 1 d (, n = 2), 2 d (, n = 2), or 3 d (, n = 8) with HRRT PET camera. Immediately after being scanned, mice were dissected and radioactivity levels in tumors were determined with -counter. After reconstruction of images, VOIs were drawn over tumors and radioactivity amounts were calculated. (A) After correction for partial-volume effects, PET-assessed (image-derived) tumor radioactivity values were plotted as function of ex vivo-assessed (-counter-derived) tumor radioactivity values. Ratio of ex vivo-assessed and PET-assessed tumor radioactivity values, corrected (B) or not corrected (C) for partial-volume effects, was plotted as function of VOI.